<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02151929</url>
  </required_header>
  <id_info>
    <org_study_id>AOM_BVS1</org_study_id>
    <nct_id>NCT02151929</nct_id>
  </id_info>
  <brief_title>Bioresorbable Vascular Scaffold in Patients With Myocardial Infarction</brief_title>
  <official_title>Bioresorbable Vascular Scaffold in Patient With ST Elevation Myocardial Infarction: a Randomized Comparison With Everolimus Eluting Stent</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>San Giuseppe Moscati Hospital</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>San Giuseppe Moscati Hospital</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Evaluation of the feasibility and safety of Bioresorbable Vascular Scaffold (BVS) in patient
      treated with primary PCI (pPCI).
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Background. Drug-eluting stent (DES) implantation may offer benefits in terms of repeat
      revascularization in patients with ST elevation myocardial infarction (STEMI). The everolimus
      eluting bioresorbable vascular scaffold (BVS) has shown efficacy and safety in stable patient
      but not in acute coronary syndromes. The study tested the feasibility and safety of BVS in
      patient treated with primary PCI (pPCI) Methods. Consecutive STEMI patients admitted within
      12 hours of symptom onset and undergoing primary angioplasty and stent implantation at a
      tertiary center with 24-hour primary PCI capability will be randomly assigned to everolimus
      eluting stent (EES) or BVS. Primary endpoints are procedural and clinical success. The MACE
      (cardiac death, non fatal myocardial infarction, target lesion revascularization (TLR)) and
      definite or probable ST will be evaluated at six months.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>May 2013</start_date>
  <completion_date type="Actual">April 2014</completion_date>
  <primary_completion_date type="Actual">August 2013</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Procedural and Clinical success</measure>
    <time_frame>Patients will be followed for the duration of hospital stay (4-8 days)</time_frame>
    <description>Procedural success: The deployment of BVS at the intended target lesion with a final residual stenosis ≤20% and a TIMI 2-3 coronary flow by visual estimation without major periprocedural complication (death, emergent CABG, coronary perforation, flow limiting coronary dissection).
Clinical success: any major in-hospital events (deaths, reinfarction, urgent revascularization, stroke, major bleedings)</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>The MACE</measure>
    <time_frame>six months</time_frame>
    <description>cumulative incidence of cardiac death, non fatal myocardial infarction and target lesion revascularization</description>
  </secondary_outcome>
  <other_outcome>
    <measure>stent thrombosis</measure>
    <time_frame>six months</time_frame>
    <description>cumulative incidence of definite or probable stent thrombosis defined according to the Academic Research Consortium definition</description>
  </other_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">100</enrollment>
  <condition>ST Elevation Acute Myocardial Infarction</condition>
  <arm_group>
    <arm_group_label>Bioresorbable Vascular Scaffold</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Implantation of of an everolimus eluting bioresorbable scaffold in patients with STEMI treated with primary PCI</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Everolimus Eluting stent</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Implantation of of an everolimus eluting stent in patients with STEMI treated with primary PCI</description>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>Bioresorbable vascular scaffold</intervention_name>
    <description>stenting of an acute thrombotic lesion in patient within STEMI</description>
    <arm_group_label>Bioresorbable Vascular Scaffold</arm_group_label>
    <other_name>BVS, ABSORB (Abbot Vascular)</other_name>
  </intervention>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>Everolimus eluting stent</intervention_name>
    <description>stenting of an acute thrombotic lesion in patient within STEMI</description>
    <arm_group_label>Everolimus Eluting stent</arm_group_label>
    <other_name>Xience Prime (Abbott Vascular)</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. chest pain for more than 30 minutes;

          2. ST-segment elevation of 1 mm or more in 2 or more contiguous electrocardiograph leads
             or with presumably new left bundle-branch block

        Exclusion Criteria:

          1. Active internal bleeding or a history of bleeding diathesis within the previous 30
             days;

          2. Contraindication to dual antiplatelet therapy for 12 months;

          3. Known allergy to everolimus;

          4. A history of stroke within 30 days or any history of hemorrhagic stroke;

          5. History, symptoms, or findings suggestive of aortic dissection;

          6. High-likelihood of death within BVS resorbtion time;

          7. Cardiogenic shock;

          8. Infarct artery reference diameter, &lt;2.0 mm or &gt;3.7 mm (i.e. not suitable for currently
             available BVS sizes);

          9. Pregnancy;

         10. Participation in other trials
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>85 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Emilio Di Lorenzo, MD PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Division of Cardiology AO Moscati Avellino ITALY</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Division of Cardiology Ao Moscati</name>
      <address>
        <city>Avellino</city>
        <zip>83100</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Italy</country>
  </location_countries>
  <reference>
    <citation>Di Lorenzo E, Carbone G, Sauro L, Casafina A, Capasso M, Sauro R. Bare-metal stents versus drug-eluting stents for primary angioplasty: long-term outcome. Curr Cardiol Rep. 2011 Oct;13(5):459-64. doi: 10.1007/s11886-011-0207-0. Review.</citation>
    <PMID>21792636</PMID>
  </reference>
  <reference>
    <citation>De Luca G, Dirksen MT, Spaulding C, Kelbaek H, Schalij M, Thuesen L, van der Hoeven B, Vink MA, Kaiser C, Musto C, Chechi T, Spaziani G, Díaz de la Llera LS, Pasceri V, Di Lorenzo E, Violini R, Cortese G, Suryapranata H, Stone GW; Drug-Eluting Stent in Primary Angioplasty (DESERT) Cooperation. Drug-eluting vs bare-metal stents in primary angioplasty: a pooled patient-level meta-analysis of randomized trials. Arch Intern Med. 2012 Apr 23;172(8):611-21; discussion 621-2. doi: 10.1001/archinternmed.2012.758. Review.</citation>
    <PMID>22529227</PMID>
  </reference>
  <reference>
    <citation>Di Lorenzo E, Sauro R, Varricchio A, Capasso M, Lanzillo T, Manganelli F, Mariello C, Siano F, Pagliuca MR, Stanco G, Rosato G, De Luca G. Benefits of drug-eluting stents as compared to bare metal stent in ST-segment elevation myocardial infarction: four year results of the PaclitAxel or Sirolimus-Eluting stent vs bare metal stent in primary angiOplasty (PASEO) randomized trial. Am Heart J. 2009 Oct;158(4):e43-50. doi: 10.1016/j.ahj.2009.03.016.</citation>
    <PMID>19781402</PMID>
  </reference>
  <reference>
    <citation>Di Lorenzo E, De Luca G, Sauro R, Varricchio A, Capasso M, Lanzillo T, Manganelli F, Mariello C, Siano F, Pagliuca MR, Stanco G, Rosato G. The PASEO (PaclitAxel or Sirolimus-Eluting Stent Versus Bare Metal Stent in Primary Angioplasty) Randomized Trial. JACC Cardiovasc Interv. 2009 Jun;2(6):515-23. doi: 10.1016/j.jcin.2009.03.012.</citation>
    <PMID>19539255</PMID>
  </reference>
  <reference>
    <citation>Ormiston JA, Serruys PW, Regar E, Dudek D, Thuesen L, Webster MW, Onuma Y, Garcia-Garcia HM, McGreevy R, Veldhof S. A bioabsorbable everolimus-eluting coronary stent system for patients with single de-novo coronary artery lesions (ABSORB): a prospective open-label trial. Lancet. 2008 Mar 15;371(9616):899-907. doi: 10.1016/S0140-6736(08)60415-8.</citation>
    <PMID>18342684</PMID>
  </reference>
  <reference>
    <citation>Serruys PW, Onuma Y, Ormiston JA, de Bruyne B, Regar E, Dudek D, Thuesen L, Smits PC, Chevalier B, McClean D, Koolen J, Windecker S, Whitbourn R, Meredith I, Dorange C, Veldhof S, Miquel-Hebert K, Rapoza R, García-García HM. Evaluation of the second generation of a bioresorbable everolimus drug-eluting vascular scaffold for treatment of de novo coronary artery stenosis: six-month clinical and imaging outcomes. Circulation. 2010 Nov 30;122(22):2301-12. doi: 10.1161/CIRCULATIONAHA.110.970772. Epub 2010 Nov 15.</citation>
    <PMID>21098436</PMID>
  </reference>
  <verification_date>May 2014</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>May 22, 2014</study_first_submitted>
  <study_first_submitted_qc>May 30, 2014</study_first_submitted_qc>
  <study_first_posted type="Estimate">June 2, 2014</study_first_posted>
  <last_update_submitted>May 30, 2014</last_update_submitted>
  <last_update_submitted_qc>May 30, 2014</last_update_submitted_qc>
  <last_update_posted type="Estimate">June 2, 2014</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>San Giuseppe Moscati Hospital</investigator_affiliation>
    <investigator_full_name>Emilio Di Lorenzo MD PhD</investigator_full_name>
    <investigator_title>Dott. Emilio Di Lorenzo</investigator_title>
  </responsible_party>
  <keyword>myocardial infarction</keyword>
  <keyword>primary PCI</keyword>
  <keyword>stent</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Infarction</mesh_term>
    <mesh_term>Myocardial Infarction</mesh_term>
    <mesh_term>ST Elevation Myocardial Infarction</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Everolimus</mesh_term>
    <mesh_term>Sirolimus</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

